Alibaba's stock is trading near all-time lows despite stabilizing fundamentals, a normalizing local regulatory landscape, and management's emphasis on AI integration. Concerns over Alibaba's market...

The stock market is closing in on its all-time high. The S&P 500 is up over 20% in 2023, with less than three weeks to go in the year.

Pinduoduo has relied on cutthroat prices and creative group-buying plans to fuel growth.

Alibaba's (BABA) DAMO Academy introduces large language models designed for Southeast Asia.

Alibaba stock is trading at a historically low multiple and deserves your attention.

Shortly before he died last month, Charlie Munger told CNBC, “My game in life was always to avoid all standard ways of failing

In line with expectations, Michael Burry‘s Scion Asset Management experienced a notable setback last month, as revealed by the Q3 13-F securities filings.

Chinese consumer prices fell 0.5% from a year earlier in November, while economists expected a drop of 0.2%.

Alibaba's stock price has significantly declined, making it an attractive investment opportunity. The company's fundamentals remain strong, with solid revenue growth and positive free cash flow. Th...

Chinese stocks face pressure Friday over the nation's economic woes and slowing GDP growth. Yahoo Finance Markets Reporter Jared Blikre analyzes the drivers behind weaknesses in publicly traded Chi...

Jack Ma's family trust sale of shares represents a substantial influx into the market, adding more volatility to BABA. The Biden-Xi meeting signals a shift towards cooperation, potentially normaliz...

China needs consistency in its policy to help revive the economy, says Fred Hu from Primavera Capital. He adds that Alibaba still has a lot of potential despite the challenges the company has faced...

Capital Economics sees strong Chinese consumer spending to start 2024, but growth may peter out over the full year.

Shares of China's e-commerce giant Alibaba continue to lose ground despite the company's clear top- and bottom-line growth. Pharmaceutical outfit Bristol-Myers Squibb has had a tough year.

In arguably most circumstances, when you see stocks at 52-week lows, you should avoid them. Based on prevailing market theory, equity valuations culminate from the most recent publicly available in...